Showing results (1111-1120 of 1,396) with videos related to

Sort By:
Pageof 140
JCO Precision Oncology|February 9, 2022
Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM StudyMatthew J Wongchenko, Antoni Ribas, Paolo A Ascierto, et al.
JCO Precision Oncology|February 9, 2022
Minimally Invasive Real-Time Detection of Actionable Mutations in Patients With Metastatic Solid Tumors Using Fine-Needle and Liquid BiopsiesKyaw L Aung, Philippe L Bedard, Celeste Yu, et al.
JCO Precision Oncology|February 9, 2022
Economic Evaluations of Next-Generation Precision Oncology: A Critical ReviewDeirdre Weymann, Reka Pataky, Dean A Regier
JCO Precision Oncology|February 9, 2022
ALK Testing Trends and Patterns Among Community Practices in the United StatesPeter B Illei, William Wong, Ning Wu, et al.
JCO Precision Oncology|February 9, 2022
Bayesian Adaptive Design for Finding the Maximum Tolerated Sequence of Doses in Multicycle Dose-Finding Clinical TrialsJiaying Lyu, Emily Curran, Yuan Ji
JCO Precision Oncology|February 9, 2022
Year 1 in the Molecular Era of Pediatric Brain Tumor Diagnosis: Application of Universal Clinical Targeted Sequencing in an Unselected Cohort of ChildrenBonnie L Cole, Christina M Lockwood, Shannon Stasi, et al.
JCO Precision Oncology|February 17, 2022
Use of Real-World Data for the Research, Development, and Evaluation of Oncology Precision MedicinesJan R R Lewis, Ian Kerridge, Wendy Lipworth
JCO Precision Oncology|February 17, 2022
Androgen Receptor Immunohistochemistry as a Companion Diagnostic Approach to Predict Clinical Response to Enzalutamide in Triple-Negative Breast CancerVarun Kumar, Jianjun Yu, Vernon Phan, et al.
JCO Precision Oncology|March 16, 2022
Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic ChemotherapyHiroko Masuda, Kenichi Harano, Sakiko Miura, et al.
JCO Precision Oncology|March 23, 2022
Identifying Outcomes of Patients With Advanced Pancreatic Adenocarcinoma and RECIST Stable Disease Using Radiomics AnalysisQiuxia Yang, Yize Mao, Hui Xie, et al.
Pageof 140